Table 2.

Association studies with Raynaud's phenomenon (RP) in 373 systemic lupus erythematosus patients

	RP positive	RP negative	P
	N=183	N=190
Gender (male/female)	11/172	12/178	0.90
Disease duration (months)	1 to 384	12 to 372	0.49
	Median 48 (IQR=12-72)	Median 36.0 (IQR=12-72)
Age at diagnosis (years)	16-73	16-64	0.02
	Median 33 (IQR=24-42)	Median 29.5 (IQR=22-38)
Tobacco exposure	60/160 - 37.5%	60/173 -34.6%	0.59
Discoid lesion	28/173 - 16.2%	20/182 - 10.9%	0.15
Butterfly rash	99/173 - 57.2%	96/178 - 53.6%	0.53
Photosensitivity	134/179 - 74.8%	129/188 - 68.6%	0.18
Oral ulcers	80/174 - 45.9%	80/185 - 43.2%	0.60
Arthritis	105/183 - 57.3%	117/188 - 62.2%	0.34
Serositis	14/98 - 14.2%	33/120 - 27.5%	0.01
Hemolitic anemia	8/176 - 4.5%	21/188 - 11.1%	0.01
Leukopenia	51/176 - 28.9%	47/183 - 25.7%	0.48
Thrombocytopenia	49/172 - 28.4%	37/181- 20.4%	0.07
Glomerulonephritis	65/ 183 - 35.5%	102/190 - 53.6%	0.0004
Seizures	13/176 - 7.3%	15/189 - 13.2%	0.06
Psychosis	8/98 - 8.1%	7/117 - 5.9%	0.53
Anti-Ro	68/169 - 40.2%	60/176 - 34.1%	0.23
Anti-La	37/169 - 21.8%	29/176 - 16.4%	0.20
Anti-Sm	49/167 - 29.3%	32/173 - 18.5%	0.01
Anti-dsDNA	59/168 - 35.1%	65/182 - 35.7%	0.90
Anti-RNP	55/126 - 43.6%	28/140 - 20%	<0.0001
Anticardiolpin IgG	19/170 - 11.1%	29/179 - 16.2%	0.17
Anticardiolpin IgG	10/170 - 5.8%	27/176 - 15.3%	0.004
Lupus anticoagulant	17/135 - 12.6%	22/146 - 15.1%	0.54
Rheumatoid factor	49/163 - 30.1%	39/159 - 24.5%	0.26